Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance, strategic product development, and optimistic market strategies. Despite some uncertainties in the European market, the company shows robust growth potential, especially in the U.S. The Q&A session indicates positive analyst sentiment and confidence in future growth. The strategic focus on expanding patient numbers and maintaining high adherence rates supports a positive outlook. However, the absence of specific guidance and European market uncertainties slightly temper the overall sentiment.
Key Financial Performance
Fourth Quarter 2025 Net Sales $321 million, more than tripling fourth quarter 2024. This growth reflects strong demand and the successful launch of Rezdiffra.
Full Year 2025 Net Sales $958 million, an exceptional launch by industry standards. This was achieved by building a market from scratch and establishing Rezdiffra as the foundational therapy in MASH.
Gross-to-Net Impact for 2025 Low end of the 20% to 30% range. This was due to effective management of commercial rebates, government rebates, co-pay assistance, and channel distribution costs.
R&D Expenses for Fourth Quarter 2025 $116.3 million, primarily due to business development activities including upfront payments for pipeline assets.
R&D Expenses for Full Year 2025 $388.5 million, reflecting investments in business development and pipeline expansion.
SG&A Expenses for Fourth Quarter 2025 $240 million, driven by support for the Rezdiffra launch.
SG&A Expenses for Full Year 2025 $813.8 million, reflecting the expected increase to support the Rezdiffra launch.
Cash Position at End of Fourth Quarter 2025 $988.6 million in cash, cash equivalents, restricted cash, and marketable securities, ensuring strong resources for ongoing operations and pipeline development.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Rezdiffra launch: First full year on the market achieved nearly $1 billion in net sales, solidifying Rezdiffra as the foundational therapy in MASH.
Pipeline development: Added an oral GLP-1, a late-stage DGAT-2 inhibitor, and a portfolio of 6 preclinical siRNA targets to the pipeline, all designed to complement Rezdiffra.
F4c trial: Advancing the F4c trial for Rezdiffra, focusing on preventing decompensation in MASH cirrhosis.
U.S. MASH market growth: Market grew nearly 50% since 2023 and is expanding at a double-digit pace.
Ex-U.S. rollout: Initiated rollout in Germany, expanding Rezdiffra's reach.
Net sales performance: Fourth quarter 2025 net sales reached $321 million, tripling the same quarter in 2024. Full year 2025 net sales totaled $958 million.
Patient growth: Ended Q4 2025 with over 36,250 patients on Rezdiffra, up from 29,500 in Q3.
Gross-to-net impact: Full year 2025 gross-to-net impact was at the low end of the 20%-30% range, with expectations to rise to the high 30% range in 2026.
Market leadership: Rezdiffra established as the standard of care in MASH, with plans to expand into F4c and develop combination therapies.
Pipeline strategy: Focused on advancing combination therapies anchored by Rezdiffra and leveraging siRNA, DGAT-2 inhibitors, and oral GLP-1 for next-generation treatments.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approval for F4c: The company is relying on regulatory approval for Rezdiffra in F4c to double its commercial opportunity. Any delays or failure in obtaining this approval could significantly impact growth projections and strategic plans.
Gross-to-Net Impact: The gross-to-net impact is expected to increase to the high 30% range in 2026, which could affect net sales growth despite robust demand. This increase is tied to payer agreements and could pose financial challenges.
Market Competition: The MASH market is expected to support multiple therapies, and the presence of GLP-1s and other competitors could impact Rezdiffra's market share and growth trajectory.
Pipeline Development Costs: The company is investing heavily in R&D and pipeline development, including upfront payments for new assets. These costs could strain financial resources if the new programs do not yield expected results.
Supply Chain and Operational Risks: The company is expanding its operations, including an ex-U.S. rollout starting in Germany. Any disruptions in the supply chain or operational inefficiencies could impact the launch and distribution of Rezdiffra.
Economic and Market Dynamics: The MASH market is in its early stages and highly dependent on increased awareness, diagnosis, and specialist involvement. Any slowdown in these factors could hinder market growth and the adoption of Rezdiffra.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects robust net sales growth in 2026 despite an increase in gross-to-net adjustments and typical first-quarter dynamics related to benefit plan changes and insurance reverifications.
Market Expansion: The U.S. MASH market is expected to grow at a double-digit pace for the foreseeable future, driven by increased awareness, diagnosis, referrals, specialist involvement, and patients seeking care.
Product Opportunity: Rezdiffra's approval and its potential expansion into compensated MASH cirrhosis (F4c) could double its commercial opportunity, targeting approximately 245,000 patients with no approved therapies.
Pipeline Development: The company plans to initiate a drug-drug interaction study for its DGAT-2 inhibitor in 2026 and expects to begin a Phase II combination program in 2027. Additionally, a Phase I single ascending dose study of its oral GLP-1 is expected to start in the second quarter of 2026.
Strategic Positioning: Madrigal aims to build a durable category-leading franchise in MASH, leveraging Rezdiffra's foundational status and patent protection until 2045 to develop next-generation therapies and combinations.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the drivers of the meaningful growth in diagnosed patients and expectations for category growth in 2026?
A:The growth is driven by increased awareness, efforts to target specialists, and the presence of another company (Novo) driving broad awareness. The market is expected to grow with double-digit growth into the foreseeable future, with a 50% growth over a 2-year period. The focus remains on the 315,000 diagnosed patients, with no significant change in the type of patients being prescribed Rezdiffra.
Q:What is the contribution of the Germany launch to worldwide revenues and patient numbers, and expectations for 2026?
A:The contribution from Germany in 2025 was negligible, and it is expected to remain low in 2026 due to uncertainties in the ex-U.S. market. The U.S. remains the base business with strong dynamics and robust growth expected in 2026.
Q:What are the plans for the Phase II study with ervogastat and the use of NITs versus liver biopsy?
A:The Phase II study with ervogastat is planned for next year. The FDA's expectations for the Phase IIb program will guide the approach. Noninvasive tests (NITs) are expected to play a major role in Phase II assessments, as clinical care has moved past liver biopsy.
Q:How are blinded event rates for MAESTRO-NASH outcomes in F4c being tracked, and is there additional open-label NAFLD data?
A:Blinded event rates are tracking as expected, with data delivery anticipated in 2027. Additional open-label data is not expected, as significant information has already been gathered from the NAFLD-1 study, showing positive effects of Rezdiffra in severe disease cases.
Q:What is the gross-to-net evolution for 4Q and 2026, and expectations for compliance and persistence rates?
A:Gross-to-net for 4Q ended at the midpoint of the 20%-30% range, with an increase expected in 2026 to the high 30s due to commercial contracting. Compliance and persistence rates remain strong, with 60%-70% at the 1-year mark and some institutions reporting up to 90%. Wegovy's launch has not negatively impacted Rezdiffra.
Q:What is the importance of maintaining a 90% adherence rate and expectations for patient adds?
A:Maintaining high adherence rates is crucial as discontinuation leads to disease recurrence. Efforts are underway to improve persistence rates. Patient adds are expected to continue steadily, with no significant acceleration due to contracting.
Q:How does the company plan to avoid diminishing returns with multiple combination assets and what is the go/no-go criteria?
A:The company focuses on mechanistic rationale and meaningful patient outcomes. Phase II studies will determine the viability of combination assets, with a focus on adaptability and targeting specific patient subtypes.
Q:What is the role of siRNA in the treatment landscape and the timing of clinical development?
A:siRNA is seen as a complementary modality to Rezdiffra, offering a combination of a daily pill and long-acting injections. The targets are not disclosed for competitive reasons, but clinical development is progressing as planned.
Q:What is the expected growth of the F2/F3 and F4 populations over the next 5 years?
A:Double-digit growth is expected for the F2/F3 population, with the F4 population also growing as MASH becomes more widely treated and diagnosed.
Q:What are the challenges in reimbursement for long-term Rezdiffra use?
A:Reauthorizations are routine and often require physician attestation or stabilization/improvement in NITs. The belief is that Rezdiffra is a chronic therapy, and discontinuation leads to disease recurrence.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the siRNA targets for competitive reasons and did not disclose exact patient add numbers or specific growth rates for the F4 population. Additionally, they did not provide precise timelines for the development of companion diagnostics or elaborate on the exact impact of AI-supported pathology reads on trial outcomes.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CSPH
DGAT inhibitor
GLP
MASH market
RD
Slide
agonism
aim
asset
care
cirrhosis
combination Rezdiffra
disease
dose
drug
dynamic
efficacy
fatty acid
foundation
generation
goal
industry
launch
line
liver
outcome
patient
payment
prescribers
program
quality
sale
siRNA
stage
standard
study
subpopulation
therapy MASH
trial
weight loss
MDGL Transcript
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-10
Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2026 Earnings Call Transcript
Unknown5-6
The earnings call highlights a 25% revenue increase and reduced net loss, which are positive indicators. However, the lack of discussion on strategic initiatives, operational updates, or shareholder returns limits the positive impact. The increase in R&D expenses and slight decrease in cash reserves are neutral factors, balancing the overall sentiment. The absence of Q&A insights further supports a neutral stance. Without additional context on market cap or strategic developments, the stock price is likely to remain stable, resulting in a neutral prediction.
Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2025 Earnings Call Transcript
Positive2-19
The earnings call highlights strong financial performance, strategic product development, and optimistic market strategies. Despite some uncertainties in the European market, the company shows robust growth potential, especially in the U.S. The Q&A session indicates positive analyst sentiment and confidence in future growth. The strategic focus on expanding patient numbers and maintaining high adherence rates supports a positive outlook. However, the absence of specific guidance and European market uncertainties slightly temper the overall sentiment.
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
MDGL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
